Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/ANTIBE-THERAPEUTICS-INC-22293396/news/Antibe-schlie-t-erste-klinische-Studie-mit-der-neuen-Formulierung-von-Otenaproxesul-ab-45210193/?utm_source=whatsapp&utm_medium=social&utm_campaign=share